Founded in 2009 by Marc Andreessen and Ben Horowitz, Andreessen Horowitz is a venture capital firm based in Menlo Park, California. The firm specializes in incubating and investing in startups across various stages, from seed to late-stage funding. It primarily focuses on sectors such as technology, including software, cloud computing, enterprise software, and consumer Internet. Additionally, it invests in emerging fields like artificial intelligence, fintech, and healthcare, specifically targeting companies at the intersection of technology and life sciences, such as digital therapeutics and computational medicine. Andreessen Horowitz is committed to fostering innovation and supporting companies that contribute to American dynamism, while strategically avoiding investments in areas like clean energy, transportation, and consumer retail.
Operating Partner and Head of Crypto Startup Accelerator
Jay Rughani
Investment Partner
Michael Sandwick
Partner, Consumer
Joe Schmidt
Partner
Gil Shafir
Partner
Jeff Silverstein
Partner
Arianna Simpson
General Partner
Steven Sinofsky
Board Partner
Jack Soslow
Partner
Matt Spence
Partner
Nicole Stanners
Fundraise and IR Partner
Angela Strange
General Partner
Stump CPA, Jeffrey
Operating Partner
Jamie Sullivan
Partner
Robert Swan
Operating Partner
Satish Talluri
Partner
Kimberly Tan
Investment Partner
Carol Tang
Partner
Adela Tomsejova
Partner, Bio + Health
Dalton Turay
Partner
Gabriel Vasquez
Partner
Melissa Wasser
Partner of Fintech Capital Network
Tyler Wilson
Partner
Daisy Wolf
Investing Partner
Carra Wu
Partner, Crypto Investments
Kevin Wu
Partner
Guy Wuollet
Partner
Shangda Xu
Partner
Zeya Yang
Partner
JJ Yu
Partner, Capital Network
David Ulevitch
General Partner
Frank Chen
Partner
Jonathan Lai
Investment Partner
Matt Bornstein
Partner
Andrew Chen
General Partner
Past deals in Healthcare
Thatch
Series B in 2025
Thatch is a health benefits platform designed to assist businesses in managing employee healthcare effectively. It features an AI-driven service known as ThatchBot, which provides continuous support to employees for healthcare inquiries and expense management. The platform allows companies to create customized healthcare budgets that cater to individual employee needs. By offering a unified interface for healthcare spending and saving, Thatch enhances the delivery of personalized health and wellness benefits, enabling employees to navigate their healthcare options with greater ease and efficiency.
Juniper Behavioral Health
Series B in 2025
We're building behavioral health practice management software that solves the logistical pain points many clinics have today and helps them scale in the future. Essentially, our solution is an IT backbone that seamlessly integrates everything from patient onboarding to billing and everything in between, with an emphasis on integration with 3rd-party apps -- replacing the manual effort that clinicians waste time on today.
Slingshot AI
Series A in 2025
Slingshot AI is an AI research company focused on enhancing global access to mental healthcare. With a mission to address the significant gap between the demand for mental health support and the availability of providers, which currently stands at 10,000:1, Slingshot AI develops advanced technology to assist individuals in improving their mental well-being and adaptability. The company specializes in creating large language models that grasp the intricacies of human psychology, enabling users to navigate daily challenges effectively. Based in New York City and London, Slingshot AI's multidisciplinary team of researchers, engineers, and mental health experts is committed to creating tools that empower individuals to overcome obstacles and foster better connections.
Hippocratic AI
Series B in 2025
Hippocratic AI focuses on developing safety-oriented large language models specifically designed for non-diagnostic, patient-facing applications in healthcare. Unlike conventional models that are often trained on diverse internet data, which may include unreliable information, Hippocratic AI emphasizes the acquisition of evidence-based healthcare content through lawful channels. The company aims to enhance healthcare accessibility and outcomes by creating a platform that facilitates safe artificial health general intelligence. This innovation seeks to empower patients to manage their health more effectively from home, thereby improving overall health outcomes with minimal inconvenience.
Tennr
Series B in 2024
Tennr is a healthcare AI startup focused on optimizing operational efficiency in the healthcare sector by automating back-office tasks. The company has developed a workflow automation platform that tracks the lifecycle of patient referrals, allowing healthcare staff to reduce the time spent on manual workflows, information verification, and data entry. By replacing traditional faxing systems and enhancing communication processes, Tennr's technology facilitates timely care for patients and helps healthcare practices of all sizes achieve enterprise-quality automation.
Alchemy
Seed Round in 2024
Alchemy creates and implements clinical pharmacy programs and deploys technology products that use the pharmacy to expand access for patients, improve health outcomes, and increase the financial impact of a clinic's pharmacy program.
GC Therapeutics
Series A in 2024
GC Therapeutics specializes in synthetic biology to efficiently program patient-derived stem cells into various cell types. The company has developed a proprietary platform that integrates synthetic biology and artificial intelligence, enabling streamlined manufacturing and improved quality of cell therapies. Their approach allows for the rapid differentiation of pluripotent stem cells, creating unique SuperCells™ customized for specific medical conditions. The foundational technology was developed in Professor George Church's lab at Harvard Medical School, and the team at GC Therapeutics comprises dedicated biologists and tissue engineers focused on translating this innovative method into practical therapies for patients.
Thatch
Series A in 2024
Thatch is a health benefits platform designed to assist businesses in managing employee healthcare effectively. It features an AI-driven service known as ThatchBot, which provides continuous support to employees for healthcare inquiries and expense management. The platform allows companies to create customized healthcare budgets that cater to individual employee needs. By offering a unified interface for healthcare spending and saving, Thatch enhances the delivery of personalized health and wellness benefits, enabling employees to navigate their healthcare options with greater ease and efficiency.
Levels
Series A in 2024
Levels is a health and wellness company that focuses on metabolic fitness through a platform that tracks blood glucose levels in real-time. Founded in 2019, the company offers a wearable device that provides users with immediate feedback on their unique metabolism. This data enables individuals to understand how their bodies respond to various dietary and lifestyle choices, allowing them to optimize their nutrition and exercise routines to meet personal health goals. Operating as a remote-first organization, Levels aims to empower users to take control of their metabolic health.
Headway
Series D in 2024
Headway is a mental healthcare system focused on providing affordable access to mental health services. It operates a virtual network of therapists who accept insurance and offer both video and in-person sessions that can be booked entirely online. This platform enables mental healthcare providers to expand their practices while allowing individuals to save on mental health sessions. By streamlining the process of accessing therapy, Headway aims to improve the overall accessibility and affordability of mental healthcare for users.
Q Bio
Venture Round in 2024
Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.
Formation Bio
Series D in 2024
Formation Bio is a biotechnology company dedicated to accelerating drug development and enhancing patient access to new treatments by reimagining clinical trials. The company has developed a platform that scales a network of clinical trial sites integrated within existing medical practices. By utilizing a roaming cohort of certified research coordinators and leveraging advanced software and data analytics, Formation Bio enables researchers to optimize their access to human subjects for various studies, including clinical trials and psychological research. This innovative approach aims to streamline the clinical trial process, ultimately facilitating faster delivery of new therapies to patients.
Pomelo Care
Series B in 2024
Pomelo Care is a leader in evidence-based maternity care, offering comprehensive support for women throughout preconception, pregnancy, birth, postpartum, and their infant’s first year. The company combines virtual, round-the-clock clinical care with in-person doula services to create a unique support model that effectively addresses medical, behavioral, and social factors influencing maternal and infant health. By leveraging data science and machine learning, Pomelo identifies and manages risks associated with pregnancy and postpartum care, aiming to enhance health outcomes while reducing unnecessary costs. The platform provides personalized care plans and resources to meet the specific needs of pregnant individuals and newborns, collaborating with employers as well as commercial and Medicaid health plans to promote accessible and high-quality care.
Santa Ana Bio
Series B in 2024
Santa Ana Bio is a biotechnology company focused on developing precision therapies for autoimmune and inflammatory diseases. By utilizing advanced technologies such as deep cell profiling, single-cell genomics, and multi-omics platforms, the company designs targeted biologics that aim to provide effective and personalized treatment options. Through its innovative approach, Santa Ana Bio seeks to enhance patient outcomes and improve quality of life for those affected by autoimmune conditions.
Valar Labs
Series A in 2024
Valar Labs is a healthcare technology company founded in 2021 by Anirudh Joshi, Viswesh Krishna, Pranav Rajpurkar, and Damir Vrabac. The company leverages artificial intelligence to enhance cancer treatment by analyzing imaging data typically used in routine clinical care. Valar Labs provides a software platform that offers interpretable and actionable insights, assisting oncologists in making informed treatment decisions tailored to each patient's unique characteristics. Through this approach, Valar Labs aims to improve patient outcomes and support doctors in delivering optimal care for individuals battling cancer.
xAI
Series B in 2024
XAI develops artificial intelligence technologies for data analysis and decision-making. It uses machine learning algorithms to increase accuracy. XAI operates in finance, healthcare, and logistics industries.
Tennr
Series A in 2024
Tennr is a healthcare AI startup focused on optimizing operational efficiency in the healthcare sector by automating back-office tasks. The company has developed a workflow automation platform that tracks the lifecycle of patient referrals, allowing healthcare staff to reduce the time spent on manual workflows, information verification, and data entry. By replacing traditional faxing systems and enhancing communication processes, Tennr's technology facilitates timely care for patients and helps healthcare practices of all sizes achieve enterprise-quality automation.
Hippocratic AI
Series A in 2024
Hippocratic AI focuses on developing safety-oriented large language models specifically designed for non-diagnostic, patient-facing applications in healthcare. Unlike conventional models that are often trained on diverse internet data, which may include unreliable information, Hippocratic AI emphasizes the acquisition of evidence-based healthcare content through lawful channels. The company aims to enhance healthcare accessibility and outcomes by creating a platform that facilitates safe artificial health general intelligence. This innovation seeks to empower patients to manage their health more effectively from home, thereby improving overall health outcomes with minimal inconvenience.
Ambience Healthcare
Series B in 2024
Ambience Healthcare specializes in developing artificial intelligence-powered solutions aimed at enhancing the efficiency of healthcare providers. Their flagship product is a medical scribe that utilizes advanced speech recognition technology to capture clinician-patient conversations in real-time, transforming them into comprehensive notes that seamlessly integrate into electronic medical record systems. This innovative approach significantly reduces documentation time, with healthcare systems reporting an average decrease of 78%. By automating the documentation process, Ambience Healthcare aims to alleviate clinician burnout, improve coding accuracy, and ensure high-quality patient care. The company's technology not only allows clinicians to complete their charts swiftly but also enables customization to align with individual providers' styles and preferences, ultimately contributing to a more efficient healthcare environment.
Turquoise Health
Series B in 2024
Turquoise Health is a health tech company focused on simplifying healthcare administration to lower costs and reduce complexity. By leveraging data from hospital and payer machine-readable files, the company has created a marketplace that connects patients, providers, and payers. Its platform allows users to browse and compare prices for elective services offered by hospitals, as well as to compare insurance services. This functionality enables individuals to save money on elective treatments and helps healthcare organizations attract both cash-paying and insured patients. Turquoise Health aims to enhance transparency in healthcare pricing, ultimately benefiting all stakeholders involved.
Talofa
Seed Round in 2024
Talofa is building games that make players mentally and physically healthier. Their flagship game on the platform, Run Legends, got over 300,000 downloads in the first 3 months and was featured as one of the "Best New Games" by Apple and Google Play Stores. Talofa’s team has been built up with game veterans from EA, 2K, and Riot Games and the CEO, Jenny Xu, has created mobile games with over 10M downloads.
Waymark
Venture Round in 2023
Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.
Mana.bio
Seed Round in 2023
Mana.bio is an AI-based drug delivery startup that specializes in gene therapy, focusing on both DNA and RNA-based therapeutics as well as vaccines. The company utilizes advanced technology that combines machine learning with nanotechnology to enhance the development of lipid nanoparticle systems, which are crucial for oligonucleotide therapies. By identifying optimal formulations for these delivery systems, Mana.bio aims to improve drug delivery services in the healthcare industry, thereby facilitating more effective therapeutic solutions.
Headway
Series C in 2023
Headway is a mental healthcare system focused on providing affordable access to mental health services. It operates a virtual network of therapists who accept insurance and offer both video and in-person sessions that can be booked entirely online. This platform enables mental healthcare providers to expand their practices while allowing individuals to save on mental health sessions. By streamlining the process of accessing therapy, Headway aims to improve the overall accessibility and affordability of mental healthcare for users.
Betterleap
Seed Round in 2023
Betterleap is an innovative platform designed to assist healthcare professionals in advancing their careers. By leveraging artificial intelligence, it automates the job search process and provides tailored career opportunities that align with users' skills and aspirations. The platform offers curated job listings and personalized recommendations, making it easier for healthcare workers, whether seasoned practitioners or newcomers, to find roles that resonate with their values. Betterleap aims to empower its users by streamlining their job search experience through an easy-to-navigate mobile app, ultimately enhancing their chances of securing meaningful career positions in patient care.
Bold
Series A in 2023
Bold is an at-home digital fitness program designed to help older adults live their strongest, happiest, and healthiest lives. As a member, you’ll enjoy instant access to expert trainers, scientific assessments, and personalized workout plans to help you improve your strength, flexibility, and balance — so you can chase the life you want, at any age.
Pomelo Care
Series A in 2023
Pomelo Care is a leader in evidence-based maternity care, offering comprehensive support for women throughout preconception, pregnancy, birth, postpartum, and their infant’s first year. The company combines virtual, round-the-clock clinical care with in-person doula services to create a unique support model that effectively addresses medical, behavioral, and social factors influencing maternal and infant health. By leveraging data science and machine learning, Pomelo identifies and manages risks associated with pregnancy and postpartum care, aiming to enhance health outcomes while reducing unnecessary costs. The platform provides personalized care plans and resources to meet the specific needs of pregnant individuals and newborns, collaborating with employers as well as commercial and Medicaid health plans to promote accessible and high-quality care.
Caresync.website
Series A in 2023
Our telemedicine platform aims to transform the way healthcare is accessed, offering patients the flexibility to connect with trusted healthcare providers anytime, anywhere. Through our intuitive interface and advanced video conferencing capabilities, we enable seamless communication and personalized care delivery.
Hippocratic AI
Seed Round in 2023
Hippocratic AI focuses on developing safety-oriented large language models specifically designed for non-diagnostic, patient-facing applications in healthcare. Unlike conventional models that are often trained on diverse internet data, which may include unreliable information, Hippocratic AI emphasizes the acquisition of evidence-based healthcare content through lawful channels. The company aims to enhance healthcare accessibility and outcomes by creating a platform that facilitates safe artificial health general intelligence. This innovation seeks to empower patients to manage their health more effectively from home, thereby improving overall health outcomes with minimal inconvenience.
Memora Health
Venture Round in 2023
Memora Health Inc., founded in 2016 and based in San Francisco, California, develops an enterprise healthcare productivity platform aimed at automating outpatient communication and enhancing care delivery. The company partners with health systems, health plans, and digital health organizations to streamline clinical workflows, allowing clinicians to focus on their primary responsibilities while proactively engaging patients throughout their care journeys. Memora's platform digitizes high-touch processes, intelligently triaging patient-reported data to the relevant care team members and facilitating proactive, two-way communication between patients and providers. By transforming the way care is delivered, Memora Health seeks to make healthcare more actionable, accessible, and continuous.
Zus Health
Series A in 2023
Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.
Thatch
Pre Seed Round in 2023
Thatch is a health benefits platform designed to assist businesses in managing employee healthcare effectively. It features an AI-driven service known as ThatchBot, which provides continuous support to employees for healthcare inquiries and expense management. The platform allows companies to create customized healthcare budgets that cater to individual employee needs. By offering a unified interface for healthcare spending and saving, Thatch enhances the delivery of personalized health and wellness benefits, enabling employees to navigate their healthcare options with greater ease and efficiency.
Thatch
Seed Round in 2023
Thatch is a health benefits platform designed to assist businesses in managing employee healthcare effectively. It features an AI-driven service known as ThatchBot, which provides continuous support to employees for healthcare inquiries and expense management. The platform allows companies to create customized healthcare budgets that cater to individual employee needs. By offering a unified interface for healthcare spending and saving, Thatch enhances the delivery of personalized health and wellness benefits, enabling employees to navigate their healthcare options with greater ease and efficiency.
Levels
Series A in 2023
Levels is a health and wellness company that focuses on metabolic fitness through a platform that tracks blood glucose levels in real-time. Founded in 2019, the company offers a wearable device that provides users with immediate feedback on their unique metabolism. This data enables individuals to understand how their bodies respond to various dietary and lifestyle choices, allowing them to optimize their nutrition and exercise routines to meet personal health goals. Operating as a remote-first organization, Levels aims to empower users to take control of their metabolic health.
Firefly Health
Venture Round in 2022
Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.
Rezo Therapeutics
Series A in 2022
Rezo Therapeutics is a biotechnology company that focuses on developing precision therapeutics by mapping disease networks. Utilizing its proprietary Sequence to Systems to Drugs (SSD) platform, Rezo integrates various technologies, including proteomics, genetics, structural biology, chemistry, and bioinformatics, to create comprehensive molecular maps of diseases. This innovative approach enhances the identification of novel targets and therapies, particularly in oncology, where Rezo initially concentrates its efforts. The company aims to expand its therapeutic focus through collaborations and partnerships, positioning itself at the forefront of advancing treatment options across multiple disease areas.
Revero
Seed Round in 2022
Revero is an online clinic focused on treating chronic conditions through a root-cause approach. Founded in 2019 and based in San Francisco, California, the company offers personalized treatments for autoimmune and metabolic disorders using nutrition therapy and remote medical care. Revero's platform combines nutritional therapy and clinical expertise with machine learning and digital tools, allowing patients to monitor their health progress and receive tailored feedback. The primary objectives of Revero include helping patients lower blood sugar, improve metabolic health, reduce inflammation, and restore gut health.
Vicinitas Therapeutics
Series A in 2022
Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.
BigHat Biosciences
Series B in 2022
BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
Cartography Biosciences
Series A in 2022
Cartography Biosciences is a biotechnology company focused on developing cancer therapies through precision medicine. The company has created a platform-based cell therapy that utilizes single-cell analysis to identify innovative CAR-T targets. This approach allows for the design of cancer immunotherapies tailored to the safest and most effective targets. By combining molecular biology and computational methods, Cartography enables clients to advance their studies in the development of these targeted treatments, aiming to improve outcomes for cancer patients.
Ultima Genomics
Venture Round in 2022
Ultima Genomics is unleashing the power of genomics at scale. Ultima Genomics drives the scale of genomic information to enable unprecedented advances in biology and improvements in human health. The company was founded in 2016 and is based in Newark, California.
Turquoise Health
Series A in 2022
Turquoise Health is a health tech company focused on simplifying healthcare administration to lower costs and reduce complexity. By leveraging data from hospital and payer machine-readable files, the company has created a marketplace that connects patients, providers, and payers. Its platform allows users to browse and compare prices for elective services offered by hospitals, as well as to compare insurance services. This functionality enables individuals to save money on elective treatments and helps healthcare organizations attract both cash-paying and insured patients. Turquoise Health aims to enhance transparency in healthcare pricing, ultimately benefiting all stakeholders involved.
Season Health
Series A in 2022
Season is a platform that offers personalized nutrition planning for consumers. It integrates technology with advice from users' registered dietitians to help them get more out of their nutrition and make the most out of mealtime every day. The platform recommends what to eat for breakfast, lunch, and dinner based on nutritional needs, food preferences, and budget.
Memora Health
Venture Round in 2022
Memora Health Inc., founded in 2016 and based in San Francisco, California, develops an enterprise healthcare productivity platform aimed at automating outpatient communication and enhancing care delivery. The company partners with health systems, health plans, and digital health organizations to streamline clinical workflows, allowing clinicians to focus on their primary responsibilities while proactively engaging patients throughout their care journeys. Memora's platform digitizes high-touch processes, intelligently triaging patient-reported data to the relevant care team members and facilitating proactive, two-way communication between patients and providers. By transforming the way care is delivered, Memora Health seeks to make healthcare more actionable, accessible, and continuous.
Topography Health
Series A in 2022
Topography Health is a clinical trials platform designed to facilitate private practice physicians' participation in medical research. The company aids medical practices in understanding their patient demographics and recommends suitable studies that are likely to be effective and well-received. Additionally, Topography assists in patient recruitment and the hiring and management of research staff. By enabling local clinical trials, Topography Health provides patients with various health conditions access to personalized clinical trial opportunities, ultimately advancing medical research and overcoming barriers that physicians face in entering this field.
Nitra
Seed Round in 2022
Nitra is a financial technology company focused on enhancing the healthcare industry through efficient and transparent solutions. The company offers a platform that provides machine learning-powered financial software, including credit cards, loans, accounts, payments, and expense management tailored for medical professionals. Nitra's tools help healthcare providers streamline their spending and manage payments in one centralized location, offering a clear overview of daily expenses. The Nitra Visa Business Card rewards users with benefits for every transaction and provides access to discounts through a network of partners. By simplifying accounting and receipt reconciliation, Nitra aims to support healthcare providers in balancing patient care with efficient practice management, delivering modern technology and dedicated support to the sector.
Waymark
Series A in 2022
Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.
Patina
Series A in 2021
Patina is a healthcare provider focused on enhancing the aging experience for older adults and their families. The company has developed a care model that prioritizes the unique needs and values of this demographic. By offering personalized and on-demand services, Patina aims to create a healthcare experience that is both human-centered and supportive. This approach allows families to actively participate in the care of their loved ones, ensuring that older adults receive the attention and respect they deserve as they navigate the challenges of aging. Patina's mission is to empower individuals to live their best lives and maintain their dignity as they age.
Sprinter Health
Series A in 2021
Sprinter Health is an on-demand mobile health company that sends full-time nurses and phlebotomists (“Sprinters”) into the home.
ROME Therapeutics
Series B in 2021
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.
Pomelo Care
Seed Round in 2021
Pomelo Care is a leader in evidence-based maternity care, offering comprehensive support for women throughout preconception, pregnancy, birth, postpartum, and their infant’s first year. The company combines virtual, round-the-clock clinical care with in-person doula services to create a unique support model that effectively addresses medical, behavioral, and social factors influencing maternal and infant health. By leveraging data science and machine learning, Pomelo identifies and manages risks associated with pregnancy and postpartum care, aiming to enhance health outcomes while reducing unnecessary costs. The platform provides personalized care plans and resources to meet the specific needs of pregnant individuals and newborns, collaborating with employers as well as commercial and Medicaid health plans to promote accessible and high-quality care.
Turquoise Health
Seed Round in 2021
Turquoise Health is a health tech company focused on simplifying healthcare administration to lower costs and reduce complexity. By leveraging data from hospital and payer machine-readable files, the company has created a marketplace that connects patients, providers, and payers. Its platform allows users to browse and compare prices for elective services offered by hospitals, as well as to compare insurance services. This functionality enables individuals to save money on elective treatments and helps healthcare organizations attract both cash-paying and insured patients. Turquoise Health aims to enhance transparency in healthcare pricing, ultimately benefiting all stakeholders involved.
Bayesian Health
Venture Round in 2021
Bayesian Health Inc. is a digital health company based in New York, established in 2016. It specializes in an AI-driven platform that enhances patient monitoring by assessing illness severity and detecting changes in acuity. This technology integrates with hospital electronic medical records (EMR), allowing clinical staff and hospital leadership to access real-time data and insights. The platform provides actionable early detection alerts and supports decision-making in complex clinical environments, ultimately optimizing patient care throughout their hospital stay. By leveraging existing investments in EMR systems, Bayesian Health enables healthcare providers to make informed, data-driven decisions that improve safety and efficiency in patient management.
Zus Health
Series A in 2021
Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.
Memora Health
Venture Round in 2021
Memora Health Inc., founded in 2016 and based in San Francisco, California, develops an enterprise healthcare productivity platform aimed at automating outpatient communication and enhancing care delivery. The company partners with health systems, health plans, and digital health organizations to streamline clinical workflows, allowing clinicians to focus on their primary responsibilities while proactively engaging patients throughout their care journeys. Memora's platform digitizes high-touch processes, intelligently triaging patient-reported data to the relevant care team members and facilitating proactive, two-way communication between patients and providers. By transforming the way care is delivered, Memora Health seeks to make healthcare more actionable, accessible, and continuous.
Headway
Series B in 2021
Headway is a mental healthcare system focused on providing affordable access to mental health services. It operates a virtual network of therapists who accept insurance and offer both video and in-person sessions that can be booked entirely online. This platform enables mental healthcare providers to expand their practices while allowing individuals to save on mental health sessions. By streamlining the process of accessing therapy, Headway aims to improve the overall accessibility and affordability of mental healthcare for users.
Firefly Health
Series B in 2021
Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.
AKASA
Series B in 2021
AKASA is a leading developer of AI-powered automation solutions tailored for the healthcare revenue cycle. The company focuses on enhancing complex workflows, which allows healthcare providers to improve revenue outcomes and operational efficiency. By automating tasks such as prior authorization and claims processing, AKASA addresses time-consuming challenges that were previously difficult to resolve at scale. Their technology leverages advanced AI and machine learning to streamline revenue cycle management, resulting in significant performance improvements. Clients have reported a 13% reduction in accounts receivable days, an 86% increase in efficiency, and the saving of over 300 hours of staff time each month. With a commitment to data security and measurable results, AKASA has garnered substantial investment to advance its mission of simplifying the financial aspects of healthcare.
Komodo Health
Series E in 2021
Komodo Health Inc. is a healthcare technology company that specializes in providing real-time healthcare intelligence and transparency through its innovative platform. Founded in 2014 and based in New York, with an additional office in San Francisco, the company offers a suite of software solutions, including its Healthcare Map, which tracks patient outcomes across the healthcare system. The platform utilizes advanced data science techniques and artificial intelligence to deliver insights that empower various stakeholders in the healthcare sector, including life science companies, payers, and providers. Key products such as Aperture, Pulse, and Serenity facilitate the analysis of complex healthcare connections, alert users to influence disease burden positively, and explore patient cohorts for deeper insights. By enabling a more cost-effective and value-driven healthcare system, Komodo Health aims to set a new standard for real-world data and analytics in the industry.
BigHat Biosciences
Series A in 2021
BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
Bold
Seed Round in 2021
Bold is an at-home digital fitness program designed to help older adults live their strongest, happiest, and healthiest lives. As a member, you’ll enjoy instant access to expert trainers, scientific assessments, and personalized workout plans to help you improve your strength, flexibility, and balance — so you can chase the life you want, at any age.
EQRx
Series B in 2021
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.
Levels
Seed Round in 2020
Levels is a health and wellness company that focuses on metabolic fitness through a platform that tracks blood glucose levels in real-time. Founded in 2019, the company offers a wearable device that provides users with immediate feedback on their unique metabolism. This data enables individuals to understand how their bodies respond to various dietary and lifestyle choices, allowing them to optimize their nutrition and exercise routines to meet personal health goals. Operating as a remote-first organization, Levels aims to empower users to take control of their metabolic health.
AKASA
Series A in 2020
AKASA is a leading developer of AI-powered automation solutions tailored for the healthcare revenue cycle. The company focuses on enhancing complex workflows, which allows healthcare providers to improve revenue outcomes and operational efficiency. By automating tasks such as prior authorization and claims processing, AKASA addresses time-consuming challenges that were previously difficult to resolve at scale. Their technology leverages advanced AI and machine learning to streamline revenue cycle management, resulting in significant performance improvements. Clients have reported a 13% reduction in accounts receivable days, an 86% increase in efficiency, and the saving of over 300 hours of staff time each month. With a commitment to data security and measurable results, AKASA has garnered substantial investment to advance its mission of simplifying the financial aspects of healthcare.
PatientPing
Series C in 2020
PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.
Topography Health
Venture Round in 2020
Topography Health is a clinical trials platform designed to facilitate private practice physicians' participation in medical research. The company aids medical practices in understanding their patient demographics and recommends suitable studies that are likely to be effective and well-received. Additionally, Topography assists in patient recruitment and the hiring and management of research staff. By enabling local clinical trials, Topography Health provides patients with various health conditions access to personalized clinical trial opportunities, ultimately advancing medical research and overcoming barriers that physicians face in entering this field.
Q Bio
Series B in 2020
Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.
Buck Stash
Series A in 2020
Buck Stash is a venture capital firm that specializes in seed, early, mid, and late stage investments. It prefers to invest in the social media business and technology sector, with a focus on software, back-end infrastructure, Internet infrastructure, cloud computing, enterprise software and services, consumer, business Internet, mobile Internet, consumer Internet, cloud computing, data-storage, social network browsers data-storage, consumer electronics, networking functions, software related biology, biotech, and medicine companies at the intersection of computer science and medicine
EQRx
Series A in 2020
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.
Komodo Health
Series C in 2020
Komodo Health Inc. is a healthcare technology company that specializes in providing real-time healthcare intelligence and transparency through its innovative platform. Founded in 2014 and based in New York, with an additional office in San Francisco, the company offers a suite of software solutions, including its Healthcare Map, which tracks patient outcomes across the healthcare system. The platform utilizes advanced data science techniques and artificial intelligence to deliver insights that empower various stakeholders in the healthcare sector, including life science companies, payers, and providers. Key products such as Aperture, Pulse, and Serenity facilitate the analysis of complex healthcare connections, alert users to influence disease burden positively, and explore patient cohorts for deeper insights. By enabling a more cost-effective and value-driven healthcare system, Komodo Health aims to set a new standard for real-world data and analytics in the industry.
AKASA
Seed Round in 2019
AKASA is a leading developer of AI-powered automation solutions tailored for the healthcare revenue cycle. The company focuses on enhancing complex workflows, which allows healthcare providers to improve revenue outcomes and operational efficiency. By automating tasks such as prior authorization and claims processing, AKASA addresses time-consuming challenges that were previously difficult to resolve at scale. Their technology leverages advanced AI and machine learning to streamline revenue cycle management, resulting in significant performance improvements. Clients have reported a 13% reduction in accounts receivable days, an 86% increase in efficiency, and the saving of over 300 hours of staff time each month. With a commitment to data security and measurable results, AKASA has garnered substantial investment to advance its mission of simplifying the financial aspects of healthcare.
insitro
Series A in 2018
Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.
Accolade
Series F in 2018
Accolade, Inc. is a technology-driven company that offers solutions to help individuals navigate the complexities of the healthcare system and workplace benefits in the United States. The company provides a cloud-based platform complemented by support from a team of health assistants and clinicians, including nurses and behavioral health specialists. Accolade's services are primarily aimed at employers who seek to enhance the healthcare experience for their employees and their families. By focusing on personalized health and benefits solutions, Accolade aims to improve healthcare outcomes while managing costs and increasing employee engagement. Founded in 2007, Accolade is headquartered in Plymouth Meeting, Pennsylvania.
Q Bio
Series A in 2018
Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.
Improbable
Series B in 2017
Improbable is a technology company focused on creating solutions for complex challenges through advanced simulations and immersive virtual environments. Founded in 2012 by Herman Narula and Rob Whitehead in London, the company aims to revolutionize gaming and entertainment by enabling next-generation gameplay in expansive, persistent virtual worlds. Its platform, SpatialOS, allows developers to harness the power of multiple cloud-based servers to simulate vast and intricate environments that exceed the capabilities of traditional computing. Beyond gaming, Improbable seeks to apply its technology to various sectors, including defense, energy, urban efficiency, healthcare, and finance, to facilitate significant social and economic improvements in the real world.
Freenome
Series A in 2017
Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.
Shield Bio
Seed Round in 2017
Shield Bio focuses on combating antibiotic resistance, which is projected to surpass cancer as a leading cause of death by 2050. With infections like gonorrhea becoming resistant to numerous antibiotics, resulting in over 820,000 new cases annually in the U.S., the urgency to address this crisis has escalated. Shield Bio has developed an innovative genomic testing platform that allows sexually transmitted infection (STI) clinics to identify antibiotic-resistant strains of pathogens. This technology enables healthcare providers to determine the most effective antibiotics for treatment, thereby improving patient outcomes and helping to prevent the further spread of antibiotic resistance. By enhancing the accuracy and speed of susceptibility testing, Shield Bio aims to tackle one of the most significant challenges in modern medicine.
Medisas
Series A in 2016
Medisas is a team of experienced and passionate clinicians, engineers, designers reinventing hospital software.
PatientPing
Series B in 2016
PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.
Zipline
Series B in 2016
Zipline Inc. is a California-based company that specializes in designing, manufacturing, and operating drones for the delivery of essential medical supplies, including vaccines, medicines, and blood. Founded in 2011 and headquartered in Half Moon Bay, the company aims to provide instant access to vital medical products for every individual globally. Since its inception, Zipline has developed a rapid delivery drone and an autonomous logistics network, allowing for efficient distribution to hospitals and health centers, particularly in remote areas. By leveraging its proprietary fixed-wing drone technology, Zipline facilitates timely deliveries that support the medical community and enhance patient care.
Accolade
Series E in 2016
Accolade, Inc. is a technology-driven company that offers solutions to help individuals navigate the complexities of the healthcare system and workplace benefits in the United States. The company provides a cloud-based platform complemented by support from a team of health assistants and clinicians, including nurses and behavioral health specialists. Accolade's services are primarily aimed at employers who seek to enhance the healthcare experience for their employees and their families. By focusing on personalized health and benefits solutions, Accolade aims to improve healthcare outcomes while managing costs and increasing employee engagement. Founded in 2007, Accolade is headquartered in Plymouth Meeting, Pennsylvania.
Freenome
Seed Round in 2016
Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.
Q Bio
Seed Round in 2016
Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.
Oration
Series A in 2015
Oration is a provider of a prescription management platform aimed at addressing inefficiencies in the American healthcare system. The company offers predictive analytics tools that enhance the prescription purchasing experience, allowing consumers to make informed decisions based on cost and personal preferences. In the past year, Oration has analyzed over one billion dollars in healthcare transactions, partnering with some of the largest companies in the industry. By focusing on meaningful and complex problems, Oration seeks to empower consumers to save money that would otherwise be lost in the healthcare system, ultimately striving to create a more effective and transparent healthcare purchasing process.
Health Via Modern Nutrition
Venture Round in 2015
Health Via Modern Nutrition has extensive industry experience in operations and supply chain management. From the acceptance of raw materials to full WADA compliance of the final product, at least three quality and purity audits are performed during the manufacturing process of H.V.M.N. products. All manufacturing facilities are located in the United States and adhere to the FDA's cGMP regulations.
Improbable
Series A in 2015
Improbable is a technology company focused on creating solutions for complex challenges through advanced simulations and immersive virtual environments. Founded in 2012 by Herman Narula and Rob Whitehead in London, the company aims to revolutionize gaming and entertainment by enabling next-generation gameplay in expansive, persistent virtual worlds. Its platform, SpatialOS, allows developers to harness the power of multiple cloud-based servers to simulate vast and intricate environments that exceed the capabilities of traditional computing. Beyond gaming, Improbable seeks to apply its technology to various sectors, including defense, energy, urban efficiency, healthcare, and finance, to facilitate significant social and economic improvements in the real world.
Human API
Series A in 2015
Human API is a digital health data network that allows consumers to easily access and share their health information from various sources, including hospitals, electronic medical records, pharmacies, labs, and wearable devices. Founded in 2013 and based in San Mateo, California, the company connects to data from 90% of US hospitals and over 300 wellness applications. The platform employs a machine learning-powered data pipeline to standardize health data, making it more accessible and actionable for medical researchers and scientists. Importantly, it empowers consumers to maintain control over their personal health data, determining which companies can access their information. This streamlined approach addresses the challenges of fragmented health data sources, facilitating efficient data sharing and utilization in the healthcare ecosystem.
Glow
Series B in 2014
Glow, Inc. is a technology company that develops mobile applications and online communities focused on women's health, particularly in areas concerning menstruation, fertility, pregnancy, and menopause. Founded in 2013 and based in San Francisco, Glow offers several applications, including Ruby By Glow, which assists with period and ovulation tracking, and Glow Nurture, designed for pregnancy tracking. The platform provides valuable insights, articles, and tips to support women throughout their reproductive journeys, whether they are trying to conceive, avoiding pregnancy, or coping with miscarriage. Additionally, Glow First is a community program aimed at making infertility treatment more accessible by allowing couples to pool resources and offering financial assistance to those who do not achieve pregnancy through accredited clinics.
SolveBio
Seed Round in 2014
SolveBio specializes in genomic intelligence, providing a platform that facilitates the integration and management of genomic data for pharmaceutical, biotech, and diagnostic organizations. By enabling these entities to connect and utilize both internal and external genomic information, SolveBio supports innovation in precision medicine and advances human health. The platform allows clients to access and distribute genomic reference data at scale, creating a dynamic interface that enhances the use of third-party information assets. This approach empowers organizations to drive discovery and improve decision-making in the rapidly evolving field of genomics.
Glow
Series A in 2013
Glow, Inc. is a technology company that develops mobile applications and online communities focused on women's health, particularly in areas concerning menstruation, fertility, pregnancy, and menopause. Founded in 2013 and based in San Francisco, Glow offers several applications, including Ruby By Glow, which assists with period and ovulation tracking, and Glow Nurture, designed for pregnancy tracking. The platform provides valuable insights, articles, and tips to support women throughout their reproductive journeys, whether they are trying to conceive, avoiding pregnancy, or coping with miscarriage. Additionally, Glow First is a community program aimed at making infertility treatment more accessible by allowing couples to pool resources and offering financial assistance to those who do not achieve pregnancy through accredited clinics.
Human API
Seed Round in 2013
Human API is a digital health data network that allows consumers to easily access and share their health information from various sources, including hospitals, electronic medical records, pharmacies, labs, and wearable devices. Founded in 2013 and based in San Mateo, California, the company connects to data from 90% of US hospitals and over 300 wellness applications. The platform employs a machine learning-powered data pipeline to standardize health data, making it more accessible and actionable for medical researchers and scientists. Importantly, it empowers consumers to maintain control over their personal health data, determining which companies can access their information. This streamlined approach addresses the challenges of fragmented health data sources, facilitating efficient data sharing and utilization in the healthcare ecosystem.
CrowdMed
Seed Round in 2013
CrowdMed, Inc. operates an online platform that utilizes prediction market technology to assist patients in diagnosing complex medical conditions. Founded in 2012 and based in San Francisco, CrowdMed connects patients with a network of medical detectives, including licensed physicians, medical students, and other healthcare professionals, to collaboratively solve challenging medical cases. By leveraging the collective intelligence of thousands of contributors, the platform provides patients with insightful diagnostic suggestions for their unresolved symptoms. This approach not only aims to expedite the diagnostic process for individuals who have struggled with chronic health issues but also seeks to reduce healthcare costs while maintaining quality care. CrowdMed's innovative model positions it as a trusted resource for patients seeking clarity and solutions in their healthcare journeys.
Massive Health
Seed Round in 2011
Massive Health is a company dedicated to promoting healthy living through innovative technology and design. Founded in 2010 and led by Aza Raskin, a former creative lead at Firefox, the company aims to make health-related information accessible and engaging for everyone. Its flagship product, The Eatery, is an iPhone application that encourages users to improve their dietary habits by allowing them to take photos of their meals. This approach not only makes tracking food consumption enjoyable but also provides valuable feedback on the healthiness of their choices, assisting users in developing healthier habits. Massive Health's focus extends to helping individuals manage chronic conditions like diabetes through diet and exercise, emphasizing a holistic approach to wellness.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.